Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Phase I/II Study of REGN5668 (MUC16 × CD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16 × CD3)

Cancer
Jill Tseng
Other Female Genital
Ovary

Study Description

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine

the highest, safe dose that can be given to participants with ovarian cancer or cancer of the

uterus

  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

Eligibility

Inclusion

  • Is a woman <18 years of age
  • Has a life expectancy of at least 3 months.
  • Is willing and able to comply with clinic visits and study-related procedures and

requirements..

Exclusion

  • Is currently receiving treatment in another study.
  • Has had a bowel obstruction within the last 3 months or is high risk for bowel obstruction
  • Has uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV)

or hepatitis C (HCV) infection; or diagnosis of immunodeficiency

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.